Group 5D: HER2-negative Breast Cancer; Antibody-Drug Conjugates (ADCs)

*These posters are also offered on a different date/time – click HERE to register. 

Poster #1076: Comparing clinical benefit of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in a large cohort of HER2-negative metastatic breast cancer (MBC).

Poster #TPS1137: Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067).